From the ∗Rheumatology Department, Carlos G. Durand Hospital, Buenos Aires, Argentina

†Rheumatology Division, Hospital das Clínicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil

‡Barbara Volcker Center for Women and Rheumatic Diseases

§Hospital for Special Surgery

∥Weill Cornell Medicine, New York, NY

¶Rheumatology Department, Hospital Clinic University of Barcelona, Barcelona, Spain

#Rheumatology Division, Instituto Nacional de Rehabilitación “Luis Guillermo Ibarra,” Mexico City, Mexico

∗∗Unidad de Reumatología, Catedra de Semiología, Hospital Córdoba, FMC, Universidad Nacional de Córdoba

††Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Argentina.

J.A.G.-P. received personal consultant fees from AbbVie, Amgen, AstraZeneca, BMS, Galápagos, GSK, Janssen, Lilly, Novartis, Pfizer Sanofi, and Roche. G.J.P.-E. received speaker fees, consultant fees, and grants from Pfizer, Janssen, GSK, Sandoz, and Sanofi. The other authors have no conflicts of interest to declare. This research received no external funding.

Author contributions: S.V.P., D.C.O.D.A., D.E., J.A.G.-P., L.J.J., P.A.M., and G.J.P.-E. contributed to the writing—original draft. G.J.P.-E. and P.A.M. contributed to the supervision, review, and editing—grammar, style, and language. All authors contributed to the article and approved the submitted version.

Correspondence: Guillermo J. Pons-Estel, MD, PhD, Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Boulevard Oroño 1024, ZIP 2000, Rosario, Argentina. E-mail: [email protected].